Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc. (NVAX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 297.24 M | -339,424,000 | 2.51 B | 1.8 B | 1.14 B |
| 2022 | 82.38 M | -787,102,000 | 2.89 B | 2.26 B | 1.7 B |
| 2021 | 454.99 M | -1,061,125,000 | 2.93 B | 2.58 B | 2.16 B |
| 2020 | 262.01 M | -231,363,000 | 955.27 M | 1.58 B | 1.25 B |
| 2019 | 7.5 M | 243.05 M | 358.97 M | 172.96 M | 97.25 M |